Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site

Alessandra Lopes, Sara Feola, Sophie Ligot, Manlio Fusciello, Gaëlle Vandermeulen, Véronique Préat, Vincenzo Cerullo

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

Kuvaus

DNA vaccines against cancer held great promises due to the generation of a specific and long-lasting immune response. However, when used as a single therapy, they are not able to drive the generated immune response into the tumor, because of the immunosuppressive microenvironment, thus limiting their use in humans. To enhance DNA vaccine efficacy, we combined a new poly-epitope DNA vaccine encoding melanoma tumor associated antigens and B16F1-specific neoantigens with an oncolytic virus administered intratumorally.
Alkuperäiskielienglanti
LehtiJournal for Immunotherapy of Cancer
Vuosikerta7
Numero1
ISSN2051-1426
DOI - pysyväislinkit
TilaJulkaistu - 10 heinäkuuta 2019
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

  • 3122 Syöpätaudit

Lainaa tätä

@article{072f736b47b84a24b1434c93b4ce7007,
title = "Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site",
abstract = "DNA vaccines against cancer held great promises due to the generation of a specific and long-lasting immune response. However, when used as a single therapy, they are not able to drive the generated immune response into the tumor, because of the immunosuppressive microenvironment, thus limiting their use in humans. To enhance DNA vaccine efficacy, we combined a new poly-epitope DNA vaccine encoding melanoma tumor associated antigens and B16F1-specific neoantigens with an oncolytic virus administered intratumorally.",
keywords = "3122 Cancers",
author = "Alessandra Lopes and Sara Feola and Sophie Ligot and Manlio Fusciello and Ga{\"e}lle Vandermeulen and V{\'e}ronique Pr{\'e}at and Vincenzo Cerullo",
year = "2019",
month = "7",
day = "10",
doi = "10.1186/s40425-019-0644-7",
language = "English",
volume = "7",
journal = "Journal for Immunotherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site. / Lopes, Alessandra; Feola, Sara; Ligot, Sophie; Fusciello, Manlio; Vandermeulen, Gaëlle; Préat, Véronique; Cerullo, Vincenzo.

julkaisussa: Journal for Immunotherapy of Cancer, Vuosikerta 7, Nro 1, 10.07.2019.

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

TY - JOUR

T1 - Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site

AU - Lopes, Alessandra

AU - Feola, Sara

AU - Ligot, Sophie

AU - Fusciello, Manlio

AU - Vandermeulen, Gaëlle

AU - Préat, Véronique

AU - Cerullo, Vincenzo

PY - 2019/7/10

Y1 - 2019/7/10

N2 - DNA vaccines against cancer held great promises due to the generation of a specific and long-lasting immune response. However, when used as a single therapy, they are not able to drive the generated immune response into the tumor, because of the immunosuppressive microenvironment, thus limiting their use in humans. To enhance DNA vaccine efficacy, we combined a new poly-epitope DNA vaccine encoding melanoma tumor associated antigens and B16F1-specific neoantigens with an oncolytic virus administered intratumorally.

AB - DNA vaccines against cancer held great promises due to the generation of a specific and long-lasting immune response. However, when used as a single therapy, they are not able to drive the generated immune response into the tumor, because of the immunosuppressive microenvironment, thus limiting their use in humans. To enhance DNA vaccine efficacy, we combined a new poly-epitope DNA vaccine encoding melanoma tumor associated antigens and B16F1-specific neoantigens with an oncolytic virus administered intratumorally.

KW - 3122 Cancers

U2 - 10.1186/s40425-019-0644-7

DO - 10.1186/s40425-019-0644-7

M3 - Article

VL - 7

JO - Journal for Immunotherapy of Cancer

JF - Journal for Immunotherapy of Cancer

SN - 2051-1426

IS - 1

ER -